Dihydroartemisinin Regulated the MMP-Mediated Cellular Microenvironment to Alleviate Rheumatoid Arthritis
Rheumatoid arthritis (RA) is an autoimmune disease with features of synovial inflammation, cartilage erosion, bone destruction, and pain and is currently lacking a satisfactory treatment strategy. Dihydroartemisinin (DHA), the active metabolite of artemisinin, has exhibited outstanding suppressive e...
Saved in:
| Published in | Research (Washington) Vol. 7; p. 0459 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
AAAS
01.01.2024
American Association for the Advancement of Science (AAAS) |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2639-5274 2639-5274 |
| DOI | 10.34133/research.0459 |
Cover
Loading…
| Abstract | Rheumatoid arthritis (RA) is an autoimmune disease with features of synovial inflammation, cartilage erosion, bone destruction, and pain and is currently lacking a satisfactory treatment strategy. Dihydroartemisinin (DHA), the active metabolite of artemisinin, has exhibited outstanding suppressive effects on RA without obvious side effects. However, the underlying mechanisms remain unclear, which limits its further clinical application. The purpose of this study is to reveal the pharmacodynamic mechanism of DHA against RA by means of a combination of single-cell RNA sequencing (RNA-seq), proteomics, as well as transcriptomics both in vivo and in vitro. In our results, DHA effectively reduced the degree of redness, swelling, and pain in RA rats and dramatically changed the synovial tissue microenvironment under the pathological state. Within this microenvironment, fibroblasts, macrophages, B cells, and endothelial cells were the major affected cell types, primarily through DHA targeting the extracellular matrix (ECM) structural constituent signaling pathway. In addition, we confirmed that DHA regulated the ECM by modulating matrix metalloproteinase 2 (MMP2) and MMP3 in the synovial tissue of RA rats. Moreover, DHA induced apoptosis in MH7A cells, further validating the bioinformatics data. In conclusion, DHA effectively reduced the inflammatory response and improved the immune microenvironment in synovial tissue by inhibiting MMP2 and MMP3. Our findings provide a basis for the application of DHA in the treatment of RA. |
|---|---|
| AbstractList | Rheumatoid arthritis (RA) is an autoimmune disease with features of synovial inflammation, cartilage erosion, bone destruction, and pain and is currently lacking a satisfactory treatment strategy. Dihydroartemisinin (DHA), the active metabolite of artemisinin, has exhibited outstanding suppressive effects on RA without obvious side effects. However, the underlying mechanisms remain unclear, which limits its further clinical application. The purpose of this study is to reveal the pharmacodynamic mechanism of DHA against RA by means of a combination of single-cell RNA sequencing (RNA-seq), proteomics, as well as transcriptomics both in vivo and in vitro. In our results, DHA effectively reduced the degree of redness, swelling, and pain in RA rats and dramatically changed the synovial tissue microenvironment under the pathological state. Within this microenvironment, fibroblasts, macrophages, B cells, and endothelial cells were the major affected cell types, primarily through DHA targeting the extracellular matrix (ECM) structural constituent signaling pathway. In addition, we confirmed that DHA regulated the ECM by modulating matrix metalloproteinase 2 (MMP2) and MMP3 in the synovial tissue of RA rats. Moreover, DHA induced apoptosis in MH7A cells, further validating the bioinformatics data. In conclusion, DHA effectively reduced the inflammatory response and improved the immune microenvironment in synovial tissue by inhibiting MMP2 and MMP3. Our findings provide a basis for the application of DHA in the treatment of RA. Rheumatoid arthritis (RA) is an autoimmune disease with features of synovial inflammation, cartilage erosion, bone destruction, and pain and is currently lacking a satisfactory treatment strategy. Dihydroartemisinin (DHA), the active metabolite of artemisinin, has exhibited outstanding suppressive effects on RA without obvious side effects. However, the underlying mechanisms remain unclear, which limits its further clinical application. The purpose of this study is to reveal the pharmacodynamic mechanism of DHA against RA by means of a combination of single-cell RNA sequencing (RNA-seq), proteomics, as well as transcriptomics both in vivo and in vitro. In our results, DHA effectively reduced the degree of redness, swelling, and pain in RA rats and dramatically changed the synovial tissue microenvironment under the pathological state. Within this microenvironment, fibroblasts, macrophages, B cells, and endothelial cells were the major affected cell types, primarily through DHA targeting the extracellular matrix (ECM) structural constituent signaling pathway. In addition, we confirmed that DHA regulated the ECM by modulating matrix metalloproteinase 2 (MMP2) and MMP3 in the synovial tissue of RA rats. Moreover, DHA induced apoptosis in MH7A cells, further validating the bioinformatics data. In conclusion, DHA effectively reduced the inflammatory response and improved the immune microenvironment in synovial tissue by inhibiting MMP2 and MMP3. Our findings provide a basis for the application of DHA in the treatment of RA.Rheumatoid arthritis (RA) is an autoimmune disease with features of synovial inflammation, cartilage erosion, bone destruction, and pain and is currently lacking a satisfactory treatment strategy. Dihydroartemisinin (DHA), the active metabolite of artemisinin, has exhibited outstanding suppressive effects on RA without obvious side effects. However, the underlying mechanisms remain unclear, which limits its further clinical application. The purpose of this study is to reveal the pharmacodynamic mechanism of DHA against RA by means of a combination of single-cell RNA sequencing (RNA-seq), proteomics, as well as transcriptomics both in vivo and in vitro. In our results, DHA effectively reduced the degree of redness, swelling, and pain in RA rats and dramatically changed the synovial tissue microenvironment under the pathological state. Within this microenvironment, fibroblasts, macrophages, B cells, and endothelial cells were the major affected cell types, primarily through DHA targeting the extracellular matrix (ECM) structural constituent signaling pathway. In addition, we confirmed that DHA regulated the ECM by modulating matrix metalloproteinase 2 (MMP2) and MMP3 in the synovial tissue of RA rats. Moreover, DHA induced apoptosis in MH7A cells, further validating the bioinformatics data. In conclusion, DHA effectively reduced the inflammatory response and improved the immune microenvironment in synovial tissue by inhibiting MMP2 and MMP3. Our findings provide a basis for the application of DHA in the treatment of RA. |
| Author | Guo, Qiuyan Guo, Zuchang Chen, Lin Wong, Yin Kwan Shen, Shengnan He, Xueling Zhang, Wenjing Chen, Jiayun Wang, Qixin Xie, Daoyuan Zhao, Minghong Xia, Fei Qiu, Chong Dai, Chuanhao Wang, Chen Lu, Tianming Wang, Jigang Pang, Huanhuan |
| AuthorAffiliation | 2 Department of Physiology, Yong Loo Lin School of Medicine , National University of Singapore , Singapore, Singapore 6 Department of Critical Care Medicine, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital , Southern University of Science and Technology) , Shenzhen 518020, Guangdong, China 5 State Key Laboratory of Antiviral Drugs, School of Pharmacy , Henan University , Kaifeng 475004, China 3 Chinese Medical Association , Beijing 100710, China 4 Laboratory of Translational Medicine Research, Deyang People’s Hospital of Chengdu University of Traditional Chinese Medicine, Deyang 618000, China 1 State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica , China Academy of Chinese Medical Sciences , Beijing 100700, China |
| AuthorAffiliation_xml | – name: 2 Department of Physiology, Yong Loo Lin School of Medicine , National University of Singapore , Singapore, Singapore – name: 4 Laboratory of Translational Medicine Research, Deyang People’s Hospital of Chengdu University of Traditional Chinese Medicine, Deyang 618000, China – name: 3 Chinese Medical Association , Beijing 100710, China – name: 6 Department of Critical Care Medicine, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital , Southern University of Science and Technology) , Shenzhen 518020, Guangdong, China – name: 5 State Key Laboratory of Antiviral Drugs, School of Pharmacy , Henan University , Kaifeng 475004, China – name: 1 State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica , China Academy of Chinese Medical Sciences , Beijing 100700, China |
| Author_xml | – sequence: 1 givenname: Qiuyan surname: Guo fullname: Guo, Qiuyan organization: State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China – sequence: 2 givenname: Qixin surname: Wang fullname: Wang, Qixin organization: State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China – sequence: 3 givenname: Jiayun surname: Chen fullname: Chen, Jiayun organization: State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China – sequence: 4 givenname: Minghong surname: Zhao fullname: Zhao, Minghong organization: State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China – sequence: 5 givenname: Tianming surname: Lu fullname: Lu, Tianming organization: State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China – sequence: 6 givenname: Zuchang surname: Guo fullname: Guo, Zuchang organization: State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China – sequence: 7 givenname: Chen surname: Wang fullname: Wang, Chen organization: State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China – sequence: 8 givenname: Yin Kwan surname: Wong fullname: Wong, Yin Kwan organization: Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore – sequence: 9 givenname: Xueling surname: He fullname: He, Xueling organization: State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China – sequence: 10 givenname: Lin surname: Chen fullname: Chen, Lin organization: State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China – sequence: 11 givenname: Wenjing surname: Zhang fullname: Zhang, Wenjing organization: Chinese Medical Association, Beijing 100710, China – sequence: 12 givenname: Chuanhao surname: Dai fullname: Dai, Chuanhao organization: State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China – sequence: 13 givenname: Shengnan surname: Shen fullname: Shen, Shengnan organization: State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China – sequence: 14 givenname: Huanhuan surname: Pang fullname: Pang, Huanhuan organization: State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China – sequence: 15 givenname: Fei surname: Xia fullname: Xia, Fei organization: State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China – sequence: 16 givenname: Chong surname: Qiu fullname: Qiu, Chong organization: State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China – sequence: 17 givenname: Daoyuan surname: Xie fullname: Xie, Daoyuan organization: Laboratory of Translational Medicine Research, Deyang People’s Hospital of Chengdu University of Traditional Chinese Medicine, Deyang 618000, China – sequence: 18 givenname: Jigang orcidid: 0000-0002-0575-0105 surname: Wang fullname: Wang, Jigang organization: State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China., State Key Laboratory of Antiviral Drugs, School of Pharmacy, Henan University, Kaifeng 475004, China., Department of Critical Care Medicine, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, Guangdong, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39257420$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kstvEzEQxi1UREvplSPaI5cNfq69JxSFV6VGoArOlmPPZl3trovtjdT_HidpUIvEydbM9_1G83iNzqYwAUJvCV4wThj7ECGBibZfYC7aF-iCNqytBZX87Mn_HF2ldIcxpkTithWv0DlrqZCc4gvkP_n-wcVgYobRJz_5qbqF7TyYDK7KPVTr9Y96Dc4fAisYhpKL1drbGGDa-RimEaZc5VAthwF2e11128M8mhy8q5Yx99Fnn96gl50ZElw9vpfo15fPP1ff6pvvX69Xy5vaciFzLSWmhoOSrpPGADjjCAFJGqW4bW0JW2K4gg03WKjGdiAbyxpB-cYpiR27RNdHrgvmTt9HP5r4oIPx-hAIcatLs94OoA1rbUMJbqAtdmGN4RwXJKfdRjHAhfXxyLqfNyM4WxqNZngGfZ6ZfK-3YacJYUqIRhXC-0dCDL9nSFmXKdsyRTNBmJNmBFOlsCSiSN89Lfa3ymlZRcCPgjL6lCJ02vpssg_72n7QBOvDWejTWej9WRTb4h_bifwfwx8S-788 |
| CitedBy_id | crossref_primary_10_1186_s12943_025_02242_9 |
| Cites_doi | 10.1016/j.abb.2018.07.010 10.1186/s13036-019-0184-1 10.1016/j.biomaterials.2017.01.008 10.1002/art.41184 10.4049/jimmunol.1800304 10.1136/rmdopen-2017-000471 10.1007/s12013-013-9563-2 10.1016/j.intimp.2018.10.015 10.1016/j.jaut.2022.102950 10.1038/nrrheum.2016.91 10.1172/JCI11092 10.34133/research.0220 10.1155/2014/681678 10.1016/S0140-6736(16)30173-8 10.1093/jnci/50.2.549 10.1136/annrheumdis-2016-209775 10.1007/s11307-020-01534-4 10.1002/art.41941 10.1136/annrheumdis-2019-216655 10.7554/eLife.27041 10.1038/s41584-023-00966-w 10.1039/c4cc02595d 10.1136/ard-2022-222605 10.1136/ard.61.11.957 10.4049/jimmunol.170.2.838 10.1016/j.jep.2020.113039 10.1186/s13075-018-1720-y 10.1007/s11926-018-0764-y 10.1038/s41392-020-0160-8 10.1016/j.jaut.2016.02.008 10.1080/14397595.2019.1704976 10.1038/s41584-020-00570-2 10.1080/08923973.2017.1379087 10.1016/j.lfs.2019.05.024 10.1016/j.phymed.2019.153156 10.3390/ijms222413675 10.1007/s00223-017-0335-7 10.1016/j.phrs.2020.104901 10.1074/jbc.275.1.444 10.1016/j.biomaterials.2015.05.028 10.1016/j.coi.2021.05.011 10.3389/fimmu.2018.02762 10.1007/s00281-017-0631-3 10.1016/j.ijpharm.2020.119178 10.34133/research.0013 10.1111/j.1365-2249.2012.04634.x 10.3389/fimmu.2018.02228 10.1002/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W 10.3389/fimmu.2021.709178 10.1136/annrheumdis-2018-214783 10.34133/research.0003 10.1038/s41401-022-00978-4 10.1038/s41584-022-00793-5 10.1016/j.biopha.2024.116304 10.1016/j.biomaterials.2017.03.044 |
| ContentType | Journal Article |
| Copyright | Copyright © 2024 Qiuyan Guo et al. Copyright © 2024 Qiuyan Guo et al. Copyright © 2024 Qiuyan Guo et al. 2024 Qiuyan Guo et al. |
| Copyright_xml | – notice: Copyright © 2024 Qiuyan Guo et al. – notice: Copyright © 2024 Qiuyan Guo et al. – notice: Copyright © 2024 Qiuyan Guo et al. 2024 Qiuyan Guo et al. |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.34133/research.0459 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| EISSN | 2639-5274 |
| ExternalDocumentID | oai_doaj_org_article_a39c62106e924b5caa4406cf42fb83e0 PMC11385568 39257420 10_34133_research_0459 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: ; grantid: 82104480 |
| GroupedDBID | AAYXX ALMA_UNASSIGNED_HOLDINGS CITATION HYE M~E OK1 PGMZT RPM GROUPED_DOAJ NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c457t-7702a4e87df7aaeedad11e716884c9c7dfc1a48eb4a0586cfe76c36524bd870d3 |
| IEDL.DBID | DOA |
| ISSN | 2639-5274 |
| IngestDate | Wed Aug 27 01:29:02 EDT 2025 Thu Aug 21 18:35:27 EDT 2025 Fri Jul 11 09:29:12 EDT 2025 Thu Jan 02 22:31:54 EST 2025 Thu Apr 24 22:53:17 EDT 2025 Tue Jul 01 03:44:28 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | Copyright © 2024 Qiuyan Guo et al. Exclusive licensee Science and Technology Review Publishing House. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY 4.0). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c457t-7702a4e87df7aaeedad11e716884c9c7dfc1a48eb4a0586cfe76c36524bd870d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work. |
| ORCID | 0000-0002-0575-0105 |
| OpenAccessLink | https://doaj.org/article/a39c62106e924b5caa4406cf42fb83e0 |
| PMID | 39257420 |
| PQID | 3102880715 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a39c62106e924b5caa4406cf42fb83e0 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11385568 proquest_miscellaneous_3102880715 pubmed_primary_39257420 crossref_citationtrail_10_34133_research_0459 crossref_primary_10_34133_research_0459 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-01-01 |
| PublicationDateYYYYMMDD | 2024-01-01 |
| PublicationDate_xml | – month: 01 year: 2024 text: 2024-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Research (Washington) |
| PublicationTitleAlternate | Research (Wash D C) |
| PublicationYear | 2024 |
| Publisher | AAAS American Association for the Advancement of Science (AAAS) |
| Publisher_xml | – name: AAAS – name: American Association for the Advancement of Science (AAAS) |
| References | Li W (e_1_3_4_58_2) 2020; 67 Cheng L (e_1_3_4_25_2) 2021; 12 Smolen JS (e_1_3_4_3_2) 2016; 388 Smolen JS (e_1_3_4_4_2) 2020; 79 e_1_3_4_9_2 Agca R (e_1_3_4_6_2) 2017; 76 Li H (e_1_3_4_57_2) 2023; 2 Ospelt C (e_1_3_4_38_2) 2017; 3 e_1_3_4_40_2 e_1_3_4_5_2 e_1_3_4_23_2 e_1_3_4_44_2 e_1_3_4_21_2 Loh C (e_1_3_4_19_2) 2019; 78 Guo Q (e_1_3_4_59_2) 2020; 5 Cheong DHJ (e_1_3_4_10_2) 2020; 158 Guo Q (e_1_3_4_55_2) 2024; 173 Müller-Ladner U (e_1_3_4_31_2) 2002; 61 Shaker O (e_1_3_4_53_2) 2013; 67 Liu W (e_1_3_4_42_2) 2018; 9 Onodera S (e_1_3_4_37_2) 2000; 275 Shin J (e_1_3_4_43_2) 2014; 50 e_1_3_4_36_2 Wang Q (e_1_3_4_56_2) 2022; 12 Fan M (e_1_3_4_16_2) 2018; 9 Takayanagi H (e_1_3_4_32_2) 2000; 43 Liu C (e_1_3_4_51_2) 2020; 260 Albrecht K (e_1_3_4_7_2) 2010; 28 e_1_3_4_2_2 Tong X (e_1_3_4_14_2) 2022; 43 Güler-Yüksel M (e_1_3_4_8_2) 2018; 102 Regev A (e_1_3_4_18_2) 2017; 6 Zhang C (e_1_3_4_39_2) 2019; 13 Chen Z (e_1_3_4_54_2) 2018; 201 e_1_3_4_41_2 Jain S (e_1_3_4_46_2) 2015; 61 Mu X (e_1_3_4_12_2) 2018; 20 Asif Amin M (e_1_3_4_30_2) 2017; 39 Zhang Y (e_1_3_4_11_2) 2020; 579 Wahba M (e_1_3_4_52_2) 2019; 229 e_1_3_4_26_2 e_1_3_4_47_2 Naylor A (e_1_3_4_35_2) 2013; 171 Yang S (e_1_3_4_34_2) 2021; 31 Adamson R (e_1_3_4_20_2) 1973; 50 Gao A (e_1_3_4_24_2) 2022; 133 Frey O (e_1_3_4_27_2) 2018; 20 Yu J (e_1_3_4_28_2) 2018; 654 Wang Z (e_1_3_4_15_2) 2021; 23 e_1_3_4_50_2 e_1_3_4_33_2 Wang Q (e_1_3_4_45_2) 2017; 122 Khakzad MR (e_1_3_4_13_2) 2017; 39 Bugatti S (e_1_3_4_49_2) 2014; 2014 Grillet B (e_1_3_4_29_2) 2023; 19 Rivellese F (e_1_3_4_22_2) 2020; 72 McAllister E (e_1_3_4_48_2) 2021; 71 Fan M (e_1_3_4_17_2) 2018; 65 |
| References_xml | – volume: 654 start-page: 47 year: 2018 ident: e_1_3_4_28_2 article-title: Aryl hydrocarbon receptor enhances the expression of miR-150-5p to suppress in prostate cancer progression by regulating MAP3K12 publication-title: Arch Biochem Biophys doi: 10.1016/j.abb.2018.07.010 – volume: 13 start-page: 60 year: 2019 ident: e_1_3_4_39_2 article-title: Long non-coding RNA PVT1 knockdown suppresses fibroblast-like synoviocyte inflammation and induces apoptosis in rheumatoid arthritis through demethylation of sirt6 publication-title: J Biol Eng doi: 10.1186/s13036-019-0184-1 – volume: 122 start-page: 10 year: 2017 ident: e_1_3_4_45_2 article-title: Targeting NF-kB signaling with polymeric hybrid micelles that co-deliver siRNA and dexamethasone for arthritis therapy publication-title: Biomaterials doi: 10.1016/j.biomaterials.2017.01.008 – volume: 72 start-page: 714 issue: 5 year: 2020 ident: e_1_3_4_22_2 article-title: B cell synovitis and clinical phenotypes in rheumatoid arthritis: Relationship to disease stages and drug exposure publication-title: Arthritis Rheumatol doi: 10.1002/art.41184 – volume: 201 start-page: 2472 issue: 8 year: 2018 ident: e_1_3_4_54_2 article-title: Therapeutic potential of mesenchymal cell-derived miRNA-150-5p-expressing exosomes in rheumatoid arthritis mediated by the modulation of MMP14 and VEGF publication-title: J Immunol doi: 10.4049/jimmunol.1800304 – volume: 3 issue: 2 year: 2017 ident: e_1_3_4_38_2 article-title: Synovial fibroblasts in 2017 publication-title: RMD Open doi: 10.1136/rmdopen-2017-000471 – volume: 67 start-page: 735 issue: 2 year: 2013 ident: e_1_3_4_53_2 article-title: Antiangiogenic effect of methotrexate and PUVA on psoriasis publication-title: Cell Biochem Biophys doi: 10.1007/s12013-013-9563-2 – volume: 65 start-page: 233 year: 2018 ident: e_1_3_4_17_2 article-title: Dihydroartemisinin derivative DC32 attenuates collagen-induced arthritis in mice by restoring the Treg/Th17 balance and inhibiting synovitis through down-regulation of IL-6 publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2018.10.015 – volume: 133 year: 2022 ident: e_1_3_4_24_2 article-title: Tissue-resident memory T cells: The key frontier in local synovitis memory of rheumatoid arthritis publication-title: J Autoimmun doi: 10.1016/j.jaut.2022.102950 – ident: e_1_3_4_33_2 doi: 10.1038/nrrheum.2016.91 – ident: e_1_3_4_47_2 doi: 10.1172/JCI11092 – ident: e_1_3_4_2_2 doi: 10.34133/research.0220 – volume: 28 start-page: S95 issue: 5 year: 2010 ident: e_1_3_4_7_2 article-title: Side effects and management of side effects of methotrexate in rheumatoid arthritis publication-title: Clin Exp Rheumatol – volume: 2014 year: 2014 ident: e_1_3_4_49_2 article-title: B cells in rheumatoid arthritis: From pathogenic players to disease biomarkers publication-title: Biomed Res Int doi: 10.1155/2014/681678 – volume: 388 start-page: 2023 issue: 10055 year: 2016 ident: e_1_3_4_3_2 article-title: Rheumatoid arthritis publication-title: Lancet doi: 10.1016/S0140-6736(16)30173-8 – volume: 50 start-page: 549 issue: 2 year: 1973 ident: e_1_3_4_20_2 article-title: Occurrence of a primary liver carcinoma in a rhesus monkey fed aflatoxin B 1 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/50.2.549 – volume: 76 start-page: 17 issue: 1 year: 2017 ident: e_1_3_4_6_2 article-title: EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2016-209775 – volume: 23 start-page: 30 issue: 1 year: 2021 ident: e_1_3_4_15_2 article-title: The evaluation of (68)Ga-citrate PET/CT imaging for dihydroartemisinin in the treatment of rheumatoid arthritis publication-title: Mol Imaging Biol doi: 10.1007/s11307-020-01534-4 – ident: e_1_3_4_40_2 doi: 10.1002/art.41941 – volume: 79 start-page: 685 issue: 6 year: 2020 ident: e_1_3_4_4_2 article-title: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2019-216655 – volume: 6 year: 2017 ident: e_1_3_4_18_2 article-title: Human cell atlas meeting participants publication-title: Elife doi: 10.7554/eLife.27041 – volume: 19 start-page: 363 issue: 6 year: 2023 ident: e_1_3_4_29_2 article-title: Matrix metalloproteinases in arthritis: Towards precision medicine publication-title: Nat Rev Rheumatol doi: 10.1038/s41584-023-00966-w – volume: 50 start-page: 7632 issue: 57 year: 2014 ident: e_1_3_4_43_2 article-title: A hyaluronic acid-methotrexate conjugate for targeted therapy of rheumatoid arthritis publication-title: Chem Commun (Camb) doi: 10.1039/c4cc02595d – ident: e_1_3_4_21_2 doi: 10.1136/ard-2022-222605 – volume: 61 start-page: 957 issue: 11 year: 2002 ident: e_1_3_4_31_2 article-title: MMPs and rheumatoid synovial fibroblasts: Siamese twins in joint destruction? publication-title: Ann Rheum Dis doi: 10.1136/ard.61.11.957 – ident: e_1_3_4_36_2 doi: 10.4049/jimmunol.170.2.838 – volume: 260 year: 2020 ident: e_1_3_4_51_2 article-title: Anti-angiogenic effect of Shikonin in rheumatoid arthritis by downregulating PI3K/AKT and MAPKs signaling pathways publication-title: J Ethnopharmacol doi: 10.1016/j.jep.2020.113039 – volume: 20 start-page: 261 issue: 1 year: 2018 ident: e_1_3_4_27_2 article-title: Induction of chronic destructive arthritis in SCID mice by arthritogenic fibroblast-like synoviocytes derived from mice with antigen-induced arthritis publication-title: Arthritis Res Ther doi: 10.1186/s13075-018-1720-y – volume: 20 start-page: 55 issue: 9 year: 2018 ident: e_1_3_4_12_2 article-title: Artemisinins—A promising new treatment for systemic lupus erythematosus: A descriptive review publication-title: Curr Rheumatol Rep doi: 10.1007/s11926-018-0764-y – volume: 5 start-page: 73 issue: 1 year: 2020 ident: e_1_3_4_59_2 article-title: Biomolecular network-based synergistic drug combination discovery: A combination of paeoniflorin and liquiritin alleviates neuropathic pain by inhibiting neuroinflammation via suppressing the chemokine signaling pathway publication-title: Signal Transduct Target Ther doi: 10.1038/s41392-020-0160-8 – ident: e_1_3_4_41_2 doi: 10.1016/j.jaut.2016.02.008 – volume: 31 start-page: 133 issue: 1 year: 2021 ident: e_1_3_4_34_2 article-title: Comparative study of HO-1 expressing synovial lining cells between RA and OA publication-title: Mod Rheumatol doi: 10.1080/14397595.2019.1704976 – ident: e_1_3_4_23_2 doi: 10.1038/s41584-020-00570-2 – volume: 39 start-page: 348 issue: 6 year: 2017 ident: e_1_3_4_13_2 article-title: Artemisinin therapeutic efficacy in the experimental model of multiple sclerosis publication-title: Immunopharmacol Immunotoxicol doi: 10.1080/08923973.2017.1379087 – volume: 229 start-page: 67 year: 2019 ident: e_1_3_4_52_2 article-title: Vardenafil and cilostazol can improve vascular reactivity in rats with diabetes mellitus and rheumatoid arthritis co-morbidity publication-title: Life Sci doi: 10.1016/j.lfs.2019.05.024 – volume: 67 year: 2020 ident: e_1_3_4_58_2 article-title: Deciphering the chemical profile and pharmacological mechanisms of Baihu-Guizhi decoction using ultra-fast liquid chromatography-quadrupole-time-of-flight tandem mass spectrometry coupled with network pharmacology-based investigation publication-title: Phytomedicine doi: 10.1016/j.phymed.2019.153156 – ident: e_1_3_4_50_2 doi: 10.3390/ijms222413675 – volume: 102 start-page: 592 issue: 5 year: 2018 ident: e_1_3_4_8_2 article-title: Glucocorticoids, inflammation and bone publication-title: Calcif Tissue Int doi: 10.1007/s00223-017-0335-7 – volume: 158 year: 2020 ident: e_1_3_4_10_2 article-title: Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases publication-title: Pharmacol Res doi: 10.1016/j.phrs.2020.104901 – volume: 275 start-page: 444 issue: 1 year: 2000 ident: e_1_3_4_37_2 article-title: Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis publication-title: J Biol Chem doi: 10.1074/jbc.275.1.444 – volume: 61 start-page: 162 year: 2015 ident: e_1_3_4_46_2 article-title: Macrophage repolarization with targeted alginate nanoparticles containing IL-10 plasmid DNA for the treatment of experimental arthritis publication-title: Biomaterials doi: 10.1016/j.biomaterials.2015.05.028 – volume: 71 start-page: 69 year: 2021 ident: e_1_3_4_48_2 article-title: BAFF signaling in B cell metabolism publication-title: Curr Opin Immunol doi: 10.1016/j.coi.2021.05.011 – volume: 9 start-page: 2762 year: 2018 ident: e_1_3_4_16_2 article-title: DC32, a Dihydroartemisinin derivative, ameliorates collagen-induced arthritis through an Nrf2-p62-Keap1 feedback loop publication-title: Front Immunol doi: 10.3389/fimmu.2018.02762 – volume: 39 start-page: 385 issue: 4 year: 2017 ident: e_1_3_4_30_2 article-title: Synovial cellular and molecular markers in rheumatoid arthritis publication-title: Semin Immunopathol doi: 10.1007/s00281-017-0631-3 – volume: 579 year: 2020 ident: e_1_3_4_11_2 article-title: Dimeric artesunate phospholipid-conjugated liposomes as promising anti-inflammatory therapy for rheumatoid arthritis publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2020.119178 – ident: e_1_3_4_9_2 doi: 10.34133/research.0013 – volume: 171 start-page: 30 issue: 1 year: 2013 ident: e_1_3_4_35_2 article-title: The role of stromal cells in the persistence of chronic inflammation publication-title: Clin Exp Immunol doi: 10.1111/j.1365-2249.2012.04634.x – volume: 9 start-page: 2228 year: 2018 ident: e_1_3_4_42_2 article-title: Sinomenine inhibits the progression of rheumatoid arthritis by regulating the secretion of inflammatory cytokines and monocyte/macrophage subsets publication-title: Front Immunol doi: 10.3389/fimmu.2018.02228 – volume: 43 start-page: 259 issue: 2 year: 2000 ident: e_1_3_4_32_2 article-title: Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis publication-title: Arthritis Rheum doi: 10.1002/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W – volume: 12 year: 2021 ident: e_1_3_4_25_2 article-title: New insights from single-cell sequencing data: Synovial fibroblasts and synovial macrophages in rheumatoid arthritis publication-title: Front Immunol doi: 10.3389/fimmu.2021.709178 – volume: 78 start-page: 1205 issue: 9 year: 2019 ident: e_1_3_4_19_2 article-title: TNF-induced inflammatory genes escape repression in fibroblast-like synoviocytes: Transcriptomic and epigenomic analysis publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2018-214783 – ident: e_1_3_4_5_2 doi: 10.34133/research.0003 – volume: 43 start-page: 3055 issue: 12 year: 2022 ident: e_1_3_4_14_2 article-title: Artemisinin derivative SM934 in the treatment of autoimmune and inflammatory diseases: Therapeutic effects and molecular mechanisms publication-title: Acta Pharmacol Sin doi: 10.1038/s41401-022-00978-4 – ident: e_1_3_4_26_2 doi: 10.1038/s41584-022-00793-5 – volume: 173 start-page: 116304 year: 2024 ident: e_1_3_4_55_2 article-title: Glycyrrhetinic acid inhibits non-small cell lung cancer via promotion of Prdx6- and caspase-3-mediated mitochondrial apoptosis publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2024.116304 – volume: 2 start-page: 23 issue: 1 year: 2023 ident: e_1_3_4_57_2 article-title: Recent advances in nano-targeting drug delivery systems for rheumatoid arthritis treatment publication-title: Acta Mater Med – volume: 12 start-page: 1128 issue: 11 year: 2022 ident: e_1_3_4_56_2 article-title: Glycyrrhizic acid mitigates Tripterygium-glycoside-tablet-induced acute liver injury via PKM2 regulated oxidative stress publication-title: Meta – ident: e_1_3_4_44_2 doi: 10.1016/j.biomaterials.2017.03.044 |
| SSID | ssj0002170995 |
| Score | 2.2893384 |
| Snippet | Rheumatoid arthritis (RA) is an autoimmune disease with features of synovial inflammation, cartilage erosion, bone destruction, and pain and is currently... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 0459 |
| SubjectTerms | Health Science |
| Title | Dihydroartemisinin Regulated the MMP-Mediated Cellular Microenvironment to Alleviate Rheumatoid Arthritis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39257420 https://www.proquest.com/docview/3102880715 https://pubmed.ncbi.nlm.nih.gov/PMC11385568 https://doaj.org/article/a39c62106e924b5caa4406cf42fb83e0 |
| Volume | 7 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA7iyYv4dn0RQVAP1W2bNOlxXV0WoSKLgreSJildWFrZx8GLv92ZtLvsiuLFSw5pSofMJPNNM_mGkAvGecR0rjw8LfSYNZGXtYX2wBMqLuI4MApPdJOnqP_KHt_421KpL8wJq-mB64m7VWGsI4hLIguRQsa1Ugx8kM5ZkGcytC5aB5-3FEzhHgxAG6APr1kacaMObxvynOIGQEy84oUcWf9PCPN7ouSS5-ltkc0GMtJOLeo2WbPlDtluFuWEXjXM0de7ZHg_LD7MuMI8TdAf1n6gg7rYvDUUoB5NkmcvcdU5oKNrRyPMQqUJZuUtXXmj04p2RnjxHMbRQWFngGuroUEZCseCtEdeew8v3b7X1FLwNONiCiC6HShmpTC5UAocozK-byFYkpLpWEO39hWTNmOqzSXMrxWRDiMOc25gSZtwn6yXVWkPCY3jzHAhoLU583WkHO7Icss0j1UWtIg3n9tUN0TjWO9ilELA4XSRznWRoi5a5HIx_r2m2Ph15B2qajEKqbFdBxhM2hhM-pfBtMj5XNEpqALPR1Rpq9kkDRFsScBcvEUOasUvPgUwkgsWwNtyxSRWZFl9Ug4LR9ft-6FEnrej_5D-mGwEAKvqn0AnZH06ntlTgEXT7MytAGiTz4cvRV8RwA |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dihydroartemisinin+Regulated+the+MMP-Mediated+Cellular+Microenvironment+to+Alleviate+Rheumatoid+Arthritis&rft.jtitle=Research+%28Washington%29&rft.au=Guo%2C+Qiuyan&rft.au=Wang%2C+Qixin&rft.au=Chen%2C+Jiayun&rft.au=Zhao%2C+Minghong&rft.date=2024-01-01&rft.pub=AAAS&rft.eissn=2639-5274&rft.volume=7&rft_id=info:doi/10.34133%2Fresearch.0459&rft.externalDocID=PMC11385568 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2639-5274&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2639-5274&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2639-5274&client=summon |